QURE · uniQure N.V. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on QURE. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About QURE · uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Live Quote
HOLD (score +4) · 12-1 mom 74.1% · RSI 77.6 · above_both · -30.5% from high
Targets blend Wall Street consensus (11 analysts: low $34.29 / mean $58.40 / high $92.18) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
recent scout:no_anomaly 0.6h ago < cooldown 168h, no material change
The investigation reveals that the Form 4 cluster triggering this dossier consists exclusively of pre-scheduled Rule 10b5-1 plan sales and RSU withholding tax transactions — zero open-market discretionary insider purchases were detected across all filings reviewed. The sole bullish catalyst (FDA agreeing AMT-130 Phase I/II data can support an accelerated BLA for Huntington's disease) fired on June 17, 2026, producing a ~80% single-day surge from $27 to $48. The stock has since given back some gains and now trades at $46.29 with RSI(14) at 78.8 — extremely overbought entering any post-event positioning window. Options chain data is unreliable (null bid/ask across all strikes, IVs showing erroneous values), eliminating the ability to construct spread-based structures. No genuine edge detected.
The Form 4 cluster that triggered this investigation is a phantom signal: all recent 'acquisitions' are routine RSU vestings at $0 strike price across five directors and one executive (code A, not open-market P-purchase), with simultaneous small tax-hedging sales. No insider made a discretionary open-market purchase in the past 90 days. The stock nearly halved from its FDA setback low (~March 2026 bottom) but remains deeply uncertain — AMT-130's Phase I/II data is 'currently unlikely' to support a US BLA, forcing the company into a Type B FDA meeting and a UK MAA submission path instead. No material edge found in fundamentals or filings that the market has missed; the regulatory risk is well-known.